前列腺内缓释抗雄激素2-羟基氟他胺治疗局限性前列腺癌
两项临床试验(LPC-002和LPC-003)共纳入47例局限性前列腺癌男性,经直肠超声引导向前列腺内注射2-羟基氟他胺缓释制剂。LPC-002中平均剂690 mg使前列腺特异性抗原和前列腺体积较基线分别平均下降24.9%和14.0%;LPC-003中剂量增至920和1740 mg后6和8周PSA平均下降16%和23%。注射未导致激素相关副作用,3例严重不良事件均经口服抗生素治愈;作者建议为更好抗癌效果需更高剂量和更好剂量分布。
要点
- 前列腺内注射2-羟基氟他胺缓释制剂显示抗肿瘤效应,且安全可耐受。
- LPC-002平均剂量690 mg使PSA和前列腺体积较基线平均下降24.9%和14.0%。
- LPC-003剂量920和1740 mg后6和8周PSA平均下降16%和23%,未出现激素相关副作用。
核心结论
- 前列腺内注射2-羟基氟他胺缓释制剂显示抗肿瘤效应,且安全可耐受;但作者建议为获得更好抗癌效果需更高剂量和更好剂量分布。
研究设计与样本
- 两项临床试验LPC-002和LPC-003共纳入47例局限性前列腺癌男性,经直肠超声引导向前列腺内注射2-羟基氟他胺(NanoZolid®)缓释制剂。
- LPC-002在24例患者中测量6个月前列腺特异性抗原和前列腺体积变化。
- LPC-003在23例患者中通过组织病理学和磁共振成像(含波谱)评估6或8周的抗肿瘤效应,两项研究均检测血浆睾酮和2-羟基氟他胺及生活质量参数。
主要发现
- LPC-002(平均剂量690 mg)观察到前列腺特异性抗原和前列腺体积下降,平均最低值分别较基线低24.9%和14.0%。
- LPC-003剂量增至920和1740 mg后,平均前列腺特异性抗原在6和8周分别下降16%和23%。
- 磁共振成像和磁共振波谱显示治疗后形态学改变和代谢物浓度整体降低,提示抗肿瘤反应。
- 注射未导致激素相关副作用;报告3例严重不良事件,均经口服抗生素治疗缓解。
关键数值与推荐
- LPC-002平均剂量690 mg,平均最低前列腺特异性抗原较基线低24.9%,平均最低前列腺体积较基线低14.0%。
- LPC-003剂量920 mg后6周平均前列腺特异性抗原下降16%,剂量1740 mg后8周平均下降23%。
- 报告3例严重不良事件,均经口服抗生素治疗缓解。
临床怎么用
- 作者建议为获得更好抗癌效果需更高剂量和更好剂量分布。
局限性
- 作者建议为获得更好抗癌效果需更高剂量和更好剂量分布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated the tolerability, safety and antitumor effects of a novel intraprostatic depot formulation of antiandrogen 2-hydroxyflutamide (in NanoZolid®) in men with localized prostate cancer. MATERIALS AND METHODS: Two clinical trials, LPC-002 and LPC-003, were performed in a total of 47 men. The formulation was injected transrectally into the prostate under ultrasound guidance. In LPC-002 the effects on prostate specific antigen and prostate volume were measured for 6 months in 24 patients. In LPC-003 antitumor effects were evaluated by histopathology and magnetic resonance imaging including spectroscopy during 6 or 8 weeks in 23 patients. In each study testosterone and 2-hydroxyflutamide in plasma were measured as well as quality of life parameters. RESULTS: In LPC-002 (mean dose 690 mg) a reduction was observed in prostate specific antigen and prostate volume. Average nadir prostate specific antigen and prostate volume were 24.9% and 14.0% below baseline, respectively. When increasing the dose in LPC-003 to 920 and 1,740 mg, average prostate specific antigen decreased 16% and 23% after 6 and 8 weeks, respectively. Magnetic resonance imaging and magnetic resonance spectroscopy showed morphological changes and a global reduction in metabolite concentrations following treatment, indicating an antitumor response. Injections did not result in hormone related side effects. Three serious adverse events were reported and all resolved with oral antibiotic treatment. CONCLUSIONS: Intraprostatic injections of 2-hydroxyflutamide depot formulations showed antitumor effects, and proved to be safe and tolerable. However, for better anticancer effects higher doses and better dose distribution are suggested.
引用
- Tammela TL, Häggman M, Ladjevardi S, et al. An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. J Urol. 2017. PMID: 28736321. doi:10.1016/j.juro.2017.07.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。